WO2003000883A1 - Cell proliferation inhibitors containing anti-glypican 3 antibody - Google Patents
Cell proliferation inhibitors containing anti-glypican 3 antibody Download PDFInfo
- Publication number
- WO2003000883A1 WO2003000883A1 PCT/JP2002/006237 JP0206237W WO03000883A1 WO 2003000883 A1 WO2003000883 A1 WO 2003000883A1 JP 0206237 W JP0206237 W JP 0206237W WO 03000883 A1 WO03000883 A1 WO 03000883A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- cell
- glypican
- cell growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02741243A EP1411118B1 (en) | 2001-06-22 | 2002-06-21 | Cell proliferation inhibitors containing anti-glypican-3 antibody |
US10/481,524 US20040236080A1 (en) | 2001-06-22 | 2002-06-21 | Cell proliferation inhibitors containing anti-glypican 3 antibody |
KR1020037016776A KR100877176B1 (ko) | 2001-06-22 | 2002-06-21 | 항글리피칸 3항체를 포함하는 세포증식 억제제 |
DE60228721T DE60228721D1 (en) | 2001-06-22 | 2002-06-21 | Zellproliferationsinhibitoren mit anti-glypican-3-antikörper |
DK02741243T DK1411118T3 (da) | 2001-06-22 | 2002-06-21 | Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof |
KR1020097019979A KR100953520B1 (ko) | 2001-06-22 | 2002-06-21 | 항글리피칸 3항체를 포함하는 항암제 |
JP2003507268A JP4281869B2 (ja) | 2001-06-22 | 2002-06-21 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
AU2002315857A AU2002315857B2 (en) | 2001-06-22 | 2002-06-21 | Cell proliferation inhibitors containing anti-glypican 3 antibody |
CA2451493A CA2451493C (en) | 2001-06-22 | 2002-06-21 | Cell growth inhibitors containing anti-glypican 3 antibody |
HK05111542A HK1079547A1 (en) | 2001-06-22 | 2005-12-15 | Cell growth inhibitors containing anti-glypican 3 antibody |
US11/702,780 US7744880B2 (en) | 2001-06-22 | 2007-02-05 | Cell growth inhibitors containing anti-glypican 3 antibody |
AU2007201255A AU2007201255B2 (en) | 2001-06-22 | 2007-03-22 | Cell proliferation inhibitors containing anti-glypican 3 antibody |
US12/799,491 US8263077B2 (en) | 2001-06-22 | 2010-04-26 | Cell growth inhibitors containing anti-glypican 3 antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001189443 | 2001-06-22 | ||
JP2001-189443 | 2001-06-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10481524 A-371-Of-International | 2002-06-21 | ||
US11/702,780 Continuation US7744880B2 (en) | 2001-06-22 | 2007-02-05 | Cell growth inhibitors containing anti-glypican 3 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003000883A1 true WO2003000883A1 (en) | 2003-01-03 |
Family
ID=19028362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006237 WO2003000883A1 (en) | 2001-06-22 | 2002-06-21 | Cell proliferation inhibitors containing anti-glypican 3 antibody |
Country Status (15)
Country | Link |
---|---|
US (3) | US20040236080A1 (ja) |
EP (3) | EP1780273B1 (ja) |
JP (7) | JP4281869B2 (ja) |
KR (3) | KR100953520B1 (ja) |
CN (2) | CN1314803C (ja) |
AT (2) | ATE407204T1 (ja) |
AU (2) | AU2002315857B2 (ja) |
CA (1) | CA2451493C (ja) |
CY (1) | CY1113854T1 (ja) |
DE (2) | DE60228721D1 (ja) |
DK (2) | DK2208784T3 (ja) |
ES (3) | ES2399028T3 (ja) |
HK (2) | HK1079547A1 (ja) |
PT (2) | PT2208784E (ja) |
WO (1) | WO2003000883A1 (ja) |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003100429A2 (en) * | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
WO2004022739A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドまたはc端ペプチドに対する抗体 |
WO2005023301A1 (ja) * | 2003-09-04 | 2005-03-17 | Chugai Seiyaku Kabushiki Kaisha | 胆管癌治療剤および検出薬 |
WO2006022407A1 (ja) | 2004-08-24 | 2006-03-02 | Chugai Seiyaku Kabushiki Kaisha | 抗グリピカン3抗体を用いたアジュバント療法 |
WO2006046751A1 (ja) * | 2004-10-26 | 2006-05-04 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗グリピカン3抗体 |
JP2009511587A (ja) * | 2005-10-14 | 2009-03-19 | 中外製薬株式会社 | 抗グリピカン3抗体 |
WO2009041062A1 (ja) | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン3抗体 |
WO2009122667A1 (ja) | 2008-04-04 | 2009-10-08 | 中外製薬株式会社 | 肝癌治療剤 |
JP2009232848A (ja) * | 2004-07-09 | 2009-10-15 | Chugai Pharmaceut Co Ltd | 抗グリピカン3抗体 |
WO2012073985A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
WO2013047752A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 抗原の消失を促進する抗原結合分子 |
WO2013047729A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 標的抗原に対する免疫応答を誘導する抗原結合分子 |
WO2013051294A1 (ja) | 2011-10-05 | 2013-04-11 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
US8562991B2 (en) | 2008-09-26 | 2013-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody molecules that bind to IL-6 receptor |
WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
US8680247B2 (en) | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
WO2014097648A1 (ja) | 2012-12-21 | 2014-06-26 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
WO2015083764A1 (ja) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
US9399680B2 (en) | 2007-12-05 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-NR10 antibodies |
KR20170003972A (ko) | 2014-05-08 | 2017-01-10 | 추가이 세이야쿠 가부시키가이샤 | Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제 |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
WO2017159287A1 (ja) | 2016-03-14 | 2017-09-21 | 中外製薬株式会社 | 癌の治療に用いるための細胞傷害誘導治療剤 |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP2019031552A (ja) * | 2016-03-15 | 2019-02-28 | 中外製薬株式会社 | Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法 |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
US10253100B2 (en) | 2011-09-30 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
WO2020072546A2 (en) | 2018-10-01 | 2020-04-09 | Adicet Bio, Inc. | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
US10618965B2 (en) | 2011-02-25 | 2020-04-14 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
WO2020189748A1 (ja) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ |
WO2020246567A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド |
WO2020246563A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | 抗体切断部位結合分子 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
WO2022025220A1 (ja) | 2020-07-31 | 2022-02-03 | 中外製薬株式会社 | キメラ受容体を発現する細胞を含む医薬組成物 |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11708401B2 (en) | 2018-06-22 | 2023-07-25 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
US11827699B2 (en) | 2011-09-30 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
JP4281869B2 (ja) * | 2001-06-22 | 2009-06-17 | 中外製薬株式会社 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JPWO2007015529A1 (ja) | 2005-08-03 | 2009-02-19 | パナソニック株式会社 | 基地局装置、通信端末装置、およびマルチキャリア通信方法 |
US7723043B2 (en) | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
US20120190049A1 (en) * | 2010-12-10 | 2012-07-26 | University Of Washington Through Its Center For Commercialization | Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles |
JP6494507B2 (ja) | 2012-06-01 | 2019-04-03 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グリピカン−3に対する高親和性モノクローナル抗体およびその使用 |
US9926377B2 (en) * | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
CN107531755B (zh) * | 2015-01-16 | 2022-02-25 | 美侬米克国际有限公司 | 磷脂酰肌醇蛋白聚糖表位及其用途 |
DK3333192T3 (da) * | 2015-08-03 | 2021-05-31 | Cafa Therapeutics Ltd | Antistof imod glypican-3 og anvendelse deraf |
KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
CA3004438A1 (en) * | 2015-11-09 | 2017-05-18 | The Children's Hospital Of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
PE20211279A1 (es) | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
EP4138778A1 (en) | 2020-04-22 | 2023-03-01 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04228089A (ja) | 1990-05-15 | 1992-08-18 | Kanegafuchi Chem Ind Co Ltd | 高カルシウム血症治療・予防剤 |
EP0729976A1 (en) * | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP3587664B2 (ja) | 1996-10-04 | 2004-11-10 | 中外製薬株式会社 | 再構成ヒト抗hm1.24抗体 |
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
JP4228089B2 (ja) | 1997-03-11 | 2009-02-25 | 株式会社ニコン | 過電流検知機構およびそれを用いた電子閃光装置 |
US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
CN1277632A (zh) * | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
JP3445153B2 (ja) * | 1998-06-04 | 2003-09-08 | 富士通株式会社 | 電話番号一時的使用装置及び方法 |
WO2001013940A1 (fr) * | 1999-08-23 | 2001-03-01 | Chugai Seiyaku Kabushiki Kaisha | Potentialisateurs d'expression de l'antigene hm1.24 |
JP4281869B2 (ja) | 2001-06-22 | 2009-06-17 | 中外製薬株式会社 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
-
2002
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko active IP Right Grant
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Application Discontinuation
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja active Application Filing
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko active IP Right Grant
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
-
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
- 2005-12-15 HK HK05111542A patent/HK1079547A1/xx not_active IP Right Cessation
-
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
-
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
-
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
- 2008-11-07 HK HK08112277.1A patent/HK1120522A1/xx not_active IP Right Cessation
-
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Lifetime
-
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown
Non-Patent Citations (13)
Title |
---|
CAPPURO M.I. ET AL.: "Overexpression of glypican-3 human hepatocellular carcinomas determined by immunohistochemistry using a monoclonal antibody", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 219, XP002957172 * |
DATABASE BIOSIS [online] ZHU Z.W. ET AL.: "Ehanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders", XP002957176, Database accession no. 2001:212199 * |
DATABASE MEDLINE [online] ZHOU X. ET AL.: "Expression and significance of MRX7 mRNA in human hepatocellular carcinoma", XP002957177, Database accession no. 2002100044 * |
FILMUS J. ET AL.: "Glypicans in growth control and cancer", GLYCOBIOLOGY, vol. 11, no. 3, March 2001 (2001-03-01), pages 19R - 23R, XP002957179 * |
GONZALEZ A.D. ET AL.: "OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line specific manner", J. CELL. BIOL., vol. 141, no. 6, 15 June 1998 (1998-06-15), pages 1407 - 1414, XP002927346 * |
GUT, vol. 48, no. 4, April 2001 (2001-04-01), pages 558 - 564 * |
HSU H.C. ET AL.: "Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution", CANCER RES., vol. 57, no. 22, 15 November 1997 (1997-11-15), pages 5179 - 5184, XP002957175 * |
LAGE H. ET AL.: "Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5", GENE, vol. 188, no. 2, 1 April 1997 (1997-04-01), pages 151 - 156, XP004059294 * |
LIN H. ET AL.: "Frequent silencing of the GPC3 gene in ovarian cancer cell lines", CANCER RES., vol. 59, no. 4, 15 February 1999 (1999-02-15), pages 807 - 810, XP002957180 * |
MIDORIKAWA Y. ET AL.: "Glypican-3 up-regulated in hepatocellular carcinoma, inhibits fibroblast grwoth factor 2 induced cell proliferation", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 11, XP002957173 * |
PILIA G. ET AL.: "Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome", NAT. GENET., vol. 12, no. 3, March 1996 (1996-03-01), pages 241 - 247, XP002957174 * |
SAIKALI Z. ET AL.: "Expression of glypican 3 (GPC3) in embryonal tumors", INT. J. CANCER, vol. 89, no. 5, 20 September 2000 (2000-09-20), pages 418 - 422, XP002957178 * |
ZHONGHUA WAI KE ZA ZHI, vol. 37, no. 3, March 1999 (1999-03-01), pages 171 - 173 * |
Cited By (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003100429A3 (en) * | 2002-05-23 | 2004-02-19 | Sunnybrook & Womens College | Diagnosis of hepatocellular carcinoma |
US7883853B2 (en) | 2002-05-23 | 2011-02-08 | Sunnybrook Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
WO2003100429A2 (en) * | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
WO2004022739A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドまたはc端ペプチドに対する抗体 |
AU2003261941B2 (en) * | 2002-09-04 | 2008-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody against N-terminal peptide or C-terminal peptide of GPC3 solubilized in blood |
WO2005023301A1 (ja) * | 2003-09-04 | 2005-03-17 | Chugai Seiyaku Kabushiki Kaisha | 胆管癌治療剤および検出薬 |
EP2898897A2 (en) | 2004-07-09 | 2015-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
EP2314317A2 (en) | 2004-07-09 | 2011-04-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
US7919086B2 (en) | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
EP2216046A2 (en) | 2004-07-09 | 2010-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
JP2009232848A (ja) * | 2004-07-09 | 2009-10-15 | Chugai Pharmaceut Co Ltd | 抗グリピカン3抗体 |
US7871613B2 (en) | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
CN102698267A (zh) * | 2004-08-24 | 2012-10-03 | 中外制药株式会社 | 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法 |
JPWO2006022407A1 (ja) * | 2004-08-24 | 2008-05-08 | 中外製薬株式会社 | 抗グリピカン3抗体を用いたアジュバント療法 |
WO2006022407A1 (ja) | 2004-08-24 | 2006-03-02 | Chugai Seiyaku Kabushiki Kaisha | 抗グリピカン3抗体を用いたアジュバント療法 |
JP4733042B2 (ja) * | 2004-08-24 | 2011-07-27 | 中外製薬株式会社 | 抗グリピカン3抗体を用いたアジュバント療法 |
KR101300546B1 (ko) | 2004-08-24 | 2013-09-02 | 추가이 세이야쿠 가부시키가이샤 | 항 글리피칸 3 항체를 이용한 어쥬번트 요법 |
JPWO2006046751A1 (ja) * | 2004-10-26 | 2008-05-22 | 中外製薬株式会社 | 糖鎖改変抗グリピカン3抗体 |
US7867734B2 (en) | 2004-10-26 | 2011-01-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
WO2006046751A1 (ja) * | 2004-10-26 | 2006-05-04 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗グリピカン3抗体 |
JP4794457B2 (ja) * | 2004-10-26 | 2011-10-19 | 中外製薬株式会社 | 糖鎖改変抗グリピカン3抗体 |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10118959B2 (en) | 2005-10-14 | 2018-11-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US9102739B2 (en) | 2005-10-14 | 2015-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
KR101397858B1 (ko) * | 2005-10-14 | 2014-05-20 | 추가이 세이야쿠 가부시키가이샤 | 항-글리피칸-3 항체 |
JP2009511587A (ja) * | 2005-10-14 | 2009-03-19 | 中外製薬株式会社 | 抗グリピカン3抗体 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9217033B2 (en) | 2007-07-17 | 2015-12-22 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
US8680247B2 (en) | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US8497355B2 (en) | 2007-09-28 | 2013-07-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
WO2009041062A1 (ja) | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン3抗体 |
EP2584043A2 (en) | 2007-09-28 | 2013-04-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having improved kinetics in plasma |
EP2617736A1 (en) | 2007-09-28 | 2013-07-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having improved kinetics in plasma |
US9399680B2 (en) | 2007-12-05 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-NR10 antibodies |
WO2009122667A1 (ja) | 2008-04-04 | 2009-10-08 | 中外製薬株式会社 | 肝癌治療剤 |
JPWO2009122667A1 (ja) * | 2008-04-04 | 2011-07-28 | 中外製薬株式会社 | 肝癌治療剤 |
AU2009233301B2 (en) * | 2008-04-04 | 2014-01-23 | Chugai Seiyaku Kabushiki Kaisha | Liver cancer drug |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US8562991B2 (en) | 2008-09-26 | 2013-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody molecules that bind to IL-6 receptor |
US10662245B2 (en) | 2008-09-26 | 2020-05-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of reducing IL-6 activity for disease treatment |
US10066018B2 (en) | 2009-03-19 | 2018-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
US10450381B2 (en) | 2010-11-17 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Methods of treatment that include the administration of bispecific antibodies |
EP4303236A2 (en) | 2010-11-30 | 2024-01-10 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4279513A2 (en) | 2010-11-30 | 2023-11-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4303237A2 (en) | 2010-11-30 | 2024-01-10 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4279512A2 (en) | 2010-11-30 | 2023-11-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4231014A2 (en) | 2010-11-30 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP3434767A1 (en) | 2010-11-30 | 2019-01-30 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
EP4279511A2 (en) | 2010-11-30 | 2023-11-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2012073985A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US10618965B2 (en) | 2011-02-25 | 2020-04-14 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
US11718678B2 (en) | 2011-02-25 | 2023-08-08 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
EP3825325A2 (en) | 2011-03-30 | 2021-05-26 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
EP3680251A1 (en) | 2011-09-30 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules for promoting elimination of antigens |
US10253100B2 (en) | 2011-09-30 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
WO2013047729A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 標的抗原に対する免疫応答を誘導する抗原結合分子 |
WO2013047752A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 抗原の消失を促進する抗原結合分子 |
US11827699B2 (en) | 2011-09-30 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities |
WO2013051294A1 (ja) | 2011-10-05 | 2013-04-11 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
EP3617313A1 (en) | 2011-10-05 | 2020-03-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain |
WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
EP3738980A1 (en) | 2012-02-24 | 2020-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib |
WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
WO2014097648A1 (ja) | 2012-12-21 | 2014-06-26 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
US10782300B2 (en) | 2012-12-21 | 2020-09-22 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
US10451627B2 (en) | 2012-12-21 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Method for assaying soluble GPC3 protein |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
WO2015083764A1 (ja) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ |
EP3763813A1 (en) | 2013-12-04 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
KR20170003972A (ko) | 2014-05-08 | 2017-01-10 | 추가이 세이야쿠 가부시키가이샤 | Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제 |
US11760807B2 (en) | 2014-05-08 | 2023-09-19 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US10385122B2 (en) | 2014-12-19 | 2019-08-20 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-C5 antibodies |
US10738111B2 (en) | 2014-12-19 | 2020-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10023630B2 (en) | 2014-12-19 | 2018-07-17 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing C5 with anti-C5 antibodies |
US11597760B2 (en) | 2014-12-19 | 2023-03-07 | Chugai Seiyaku Kabushiki Kaisha | Method of detecting the presence of complement C5 |
US11454633B2 (en) | 2014-12-19 | 2022-09-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US11180548B2 (en) | 2015-02-05 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing IL-8 biological activity |
US10519229B2 (en) | 2015-02-05 | 2019-12-31 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding IL-8 antibodies |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
WO2017159287A1 (ja) | 2016-03-14 | 2017-09-21 | 中外製薬株式会社 | 癌の治療に用いるための細胞傷害誘導治療剤 |
US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
JP2019031552A (ja) * | 2016-03-15 | 2019-02-28 | 中外製薬株式会社 | Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法 |
US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
US11708401B2 (en) | 2018-06-22 | 2023-07-25 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
WO2020072546A2 (en) | 2018-10-01 | 2020-04-09 | Adicet Bio, Inc. | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
WO2020189748A1 (ja) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ |
WO2020246567A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド |
WO2020246563A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | 抗体切断部位結合分子 |
WO2022025220A1 (ja) | 2020-07-31 | 2022-02-03 | 中外製薬株式会社 | キメラ受容体を発現する細胞を含む医薬組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4281869B2 (ja) | 抗グリピカン3抗体を含む細胞増殖抑制剤 | |
JP4733042B2 (ja) | 抗グリピカン3抗体を用いたアジュバント療法 | |
JP5918540B2 (ja) | 抗dll3抗体 | |
US20200157231A1 (en) | Diagnosis and treatment of cancer using anti-lgr7 antibody | |
WO2005023301A1 (ja) | 胆管癌治療剤および検出薬 | |
JP4846169B2 (ja) | 細胞増殖抑制剤 | |
JPWO2007097461A1 (ja) | C型肝炎治療用抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003507268 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451493 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028125703 Country of ref document: CN Ref document number: 1020037016776 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002315857 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002741243 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002741243 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10481524 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002315857 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087019090 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002741243 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097019979 Country of ref document: KR |